Study how metabolic syndrome affects antiviral response in hepatitis B
Part of Digestive system, Hormones & metabolism, Infections clinical trials.
This study looks at people with chronic hepatitis B who are also diagnosed with metabolic syndrome (a cluster of issues like belly fat, high blood pressure, abnormal cholesterol, or high blood sugar). It aims to see how these health factors may change how well the first hepatitis B antiviral medication works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 65 and able to give informed consent
- Have chronic hepatitis B and be “ready” to start first-line antiviral treatment
- Be positive for HBeAg (a hepatitis B blood test) and meet the study’s treatment-needed criteria
- Have metabolic syndrome, meaning you have 3 or more of: belly obesity, high blood pressure, abnormal cholesterol, or high blood sugar/diabetes
- Not have certain other liver viruses or autoimmune bile duct/liver diseases (no hepatitis A/C/E/D; no autoimmune hepatitis; no primary biliary cholangitis; no primary sclerosing cholangitis)
- No recent hepatitis B antiviral use in the last 6 months and no liver/organ transplant history
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a pegylated interferon (a medicine that boosts your immune system) to your current hepatitis B treatment can help lower your hepatitis B virus levels even more. It is for people with chronic hepatitis B who have not had interferon recently and do not have fatty liver disease.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.